Evertz Pharma GmbH Becomes First German Company to Hold Bitcoin as Treasury Reserve
Evertz Pharma GmbH, a leading pharmaceutical firm based in Frankfurt, has taken a groundbreaking step by adding Bitcoin to its corporate treasury. This move makes Evertz the first company in Germany to formally establish a Bitcoin reserve, solidifying a strategic vision that began in 2020. The company recently acquired 100 BTC—valued at approximately €10 million (~$10.8 million) as of May 2025—as part of a broader effort to diversify its financial holdings and embrace emerging financial technologies.
Managing Director Dominik Evertz described Bitcoin as a “scarce, globally tradable asset” that aligns with the company’s long-term vision for financial resilience and innovation. He emphasized that incorporating Bitcoin into the company’s reserves supports a future-focused strategy and strengthens overall financial stability.
Evertz Pharma’s decision reflects a growing corporate trend: the adoption of digital assets as a hedge against inflation and currency risk. Bitcoin’s limited supply, decentralized structure, and increasing institutional recognition have made it an attractive store of value for forward-thinking companies. As regulatory clarity and mainstream adoption continue to improve, digital assets like Bitcoin are gaining legitimacy among corporate treasuries worldwide.
This strategic move also highlights Evertz Pharma’s commitment to innovation. By integrating cryptocurrency into its financial model, the company is not only enhancing its asset diversification but also positioning itself at the forefront of the digital economy. Its bold stance may inspire others in the pharmaceutical industry and beyond to explore the potential of blockchain-based assets.
In summary, Evertz Pharma’s embrace of Bitcoin marks a significant milestone in corporate crypto adoption in Germany. It underscores the rising confidence in digital assets as a store of value and signals a broader shift in how modern companies manage and protect their financial futures. Through this decision, Evertz Pharma demonstrates leadership, adaptability, and a proactive approach to navigating the evolving global financial landscape.
Disclaimer and Risk Warning
coinweck does not endorse or is responsible for any content, accuracy, quality, advertising, products, or other materials on this page. The image used in this article is for informational purposes only and is provided to us by a third party. coinweck should not be held responsible for image copyright issues. Contact us if you have any issues or concerns. Readers should do their research before taking any actions related to the company.